PLEASANTON, Calif., Aug. 1, 2025 /PRNewswire/ — DermRays, a leader in professional-grade at-home hair removal solutions, today announced a major upgrade to its Revive system and unveiled the revolutionary V10S-the world’s first 810nm diode laser device designed specifically for men. 

1. Enhanced Precision: Revive’s New 2-Point Contact System 

The upgraded Revive now features an optimized 2-contact-point applicator (reduced from 4), delivering faster, more comfortable treatments-especially on delicate areas like the forehead. “Every innovation, no matter how small, reflects our dedication to user experience,” says the DermRays engineering team. 

2. Real User Feedback Drives Innovation 

Customer insights shaped Revive’s redesign. “The new glide-on head makes treatments effortless,” noted long-time user Sarah K. DermRays remains committed to refining products based on real-world needs. 

3. Industry Trend: Medical-Grade Tech Goes Mainstream 

As consumers shift from IPL to clinically proven diode lasers for safer, longer-lasting results, DermRays leads the charge with FDA-cleared, salon-quality devices for all genders and skin types. 

4. Game-Changer for Men: V10S Diode Laser 

Launching late July 2025, the V10S is the first at-home 810nm diode laser built for male hair patterns. Its medical-grade wavelength targets coarse hair efficiently-whether for full removal or precise beard shaping. 

5. A Global Breakthrough  

“V10S fills a critical gap,” explains lead developer Mark T. “Men need durable, high-performance tools tailored to their hair density. Diode laser technology outperforms IPL for permanent reduction.” 

6. Inclusivity Meets Cutting-Edge Science 

From Revive’s unisex versatility to V10S’s male-specific engineering, DermRays redefines at-home grooming. “Salon results, personalized for every user-regardless of gender or goals.” 

About DermRays: 

DermRays specializes in medical-inspired hair removal devices, merging dermatologist-backed diode laser technology with intuitive design for safe, permanent results at home. 

SEOUL, South Korea, Aug. 1, 2025 /PRNewswire/ — Medit (www.medit.com), a global leader in digital dentistry, today introduces the Medit i900 Mobility, a next-generation intraoral scanner designed to deliver simplicity and true mobility to clinical workflows.

The Medit i900 Mobility is the latest addition to Medit’s scanner lineup, thoughtfully designed to move with the pace of everyday dentistry, wherever care happens. At the heart of the experience are four core pillars of mobility: improved clinical efficiency and workflow fluidity optimized for chair-to-chair and room-to-room use, instant usability with lite installation, enhanced patient interaction during the scanning process and a minimal learning curve that makes adoption easy from the first scan.

The i900 Mobility transforms how clinicians work, move and connect with patients by combining precision with ease of use. At the core of this experience is Medit Link Express, the company’s first iPad-native companion app, designed to simplify scan-and-send workflows through an intuitive, user-friendly interface. With real-time scan viewing and built-in patient engagement, the app transforms the iPad into a seamless bridge between clinician and patient — immediate, effortless and mobile. Purpose-built for flexibility, the i900 Mobility pairs best-in-class software with compact, responsive hardware, ready to support chairside scanning, team collaboration and care beyond the traditional clinic setting.

Designed for a new standard of mobility, key highlights of the i900 Mobility include:

• iPad-native integration via Medit Link Express — cable-free instant scanning
• Balanced, ergonomic design — enables comfortable scanning across sessions
• Real-time scan display — enhances patient engagement during the scanning process
• Minimal learning curve — intuitive from the first scan
• Optimized for chair-to-chair and room-to-room use — improved clinical efficiency and workflow fluidity
• 30mm scan depth and 10-bit color imaging — vivid clinical accuracy
• Long-duration continuous scanning on one charge — smart battery management
• Built-in Wi-Fi 6E — seamless high-speed connectivity

Together, the i900 Mobility and Medit Link Express redefine what mobility means in dentistry, reshaping how scanning fits into everyday practice. Whether at the chairside, between clinical staff, easily moving between environments, or stepping beyond the traditional clinic, it’s a more fluid, responsive way to work. This is scanning, powered by true mobility.

Pre-orders for the Medit i900 Mobility open August 1, 2025, with shipping set to begin from September 1, availability may vary by region. Medit Link Express will be available for download from the Apple App Store starting September 1. For more information and updates, visit www.medit.com.

About Medit
Medit is a global provider of 3D intraoral scanners and digital dentistry solutions based on proprietary technology. The company supports collaborative workflows between dental clinics and labs through innovative hardware and software solutions. Headquartered in Seoul, South Korea, since 2000, Medit has a strong global presence through its offices in the Americas and Europe and a distributor network spanning over 100 countries.

SEOUL, South Korea, Aug. 1, 2025 /PRNewswire/ — Medit (www.medit.com), a global leader in digital dentistry, today introduces the Medit i900 Mobility, a next-generation intraoral scanner designed to deliver simplicity and true mobility to clinical workflows.

The Medit i900 Mobility is the latest addition to Medit’s scanner lineup, thoughtfully designed to move with the pace of everyday dentistry, wherever care happens. At the heart of the experience are four core pillars of mobility: improved clinical efficiency and workflow fluidity optimized for chair-to-chair and room-to-room use, instant usability with lite installation, enhanced patient interaction during the scanning process and a minimal learning curve that makes adoption easy from the first scan.

The i900 Mobility transforms how clinicians work, move and connect with patients by combining precision with ease of use. At the core of this experience is Medit Link Express, the company’s first iPad-native companion app, designed to simplify scan-and-send workflows through an intuitive, user-friendly interface. With real-time scan viewing and built-in patient engagement, the app transforms the iPad into a seamless bridge between clinician and patient — immediate, effortless and mobile. Purpose-built for flexibility, the i900 Mobility pairs best-in-class software with compact, responsive hardware, ready to support chairside scanning, team collaboration and care beyond the traditional clinic setting.

Designed for a new standard of mobility, key highlights of the i900 Mobility include:

• iPad-native integration via Medit Link Express — cable-free instant scanning
• Balanced, ergonomic design — enables comfortable scanning across sessions
• Real-time scan display — enhances patient engagement during the scanning process
• Minimal learning curve — intuitive from the first scan
• Optimized for chair-to-chair and room-to-room use — improved clinical efficiency and workflow fluidity
• 30mm scan depth and 10-bit color imaging — vivid clinical accuracy
• Long-duration continuous scanning on one charge — smart battery management
• Built-in Wi-Fi 6E — seamless high-speed connectivity

Together, the i900 Mobility and Medit Link Express redefine what mobility means in dentistry, reshaping how scanning fits into everyday practice. Whether at the chairside, between clinical staff, easily moving between environments, or stepping beyond the traditional clinic, it’s a more fluid, responsive way to work. This is scanning, powered by true mobility.

Pre-orders for the Medit i900 Mobility open August 1, 2025, with shipping set to begin from September 1, availability may vary by region. Medit Link Express will be available for download from the Apple App Store starting September 1. For more information and updates, visit www.medit.com.

About Medit
Medit is a global provider of 3D intraoral scanners and digital dentistry solutions based on proprietary technology. The company supports collaborative workflows between dental clinics and labs through innovative hardware and software solutions. Headquartered in Seoul, South Korea, since 2000, Medit has a strong global presence through its offices in the Americas and Europe and a distributor network spanning over 100 countries.

TAIPEI, Aug. 1, 2025 /PRNewswire/ — Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), today announced the completion of a NT$60 million (approx.US$2 million) seed funding round with assistance from Mosaic Venture Lab (MVL). The round, led by Mosaic Seed Fund, also secured a matching investment from the National Development Fund, supported by the SMESA, MOEA, and the NiEA.

Founder and CEO Dr. Min-hsi Lee stated that TaiU’s two main product lines are advancing concurrently. Its lead product, a bivalent enterovirus vaccine, is in joint venture discussions with Vietnam’s largest pharmacy chain, vaccination center chain, and a CDMO. The second, a seasonal influenza Virus-Like Particle (VLP) vaccine, is gaining international attention for its ability to rapidly respond to viral mutations. This potential has attracted a major international pharmaceutical firm for discussions, while domestic MOUs with adjuvant biotech companies are creating powerful synergies to target the hundred-billion-dollar global vaccine market.

Company advisors affirmed its strategy. Dr. Mei-shang Ho, Chairperson of the Taiwan Association for Vaccine Industry (TAVI), noted, “VLP platform technology shortens development timelines. Its high safety and efficacy represent the future of next-generation vaccines and provide a solid foundation for Taiwan to meet the challenges of emerging infectious diseases.”

Professor Peter Chang, a former member of the Control Yuan with experience in vaccine investigations, added, “TaiU successfully links the ‘R&D National Team’ and the ‘Industry National Team,’ demonstrating how Taiwan can build a world-class biomedical industry ecosystem and is a crucial step in proactively expanding Taiwan’s public health and medical strength.”

Johnny Yu, TAVI Vice Chairperson and Managing Director at MVL, concluded, “Taiwan needs more innovative companies like TaiU with flexible, collaborative business models to fill critical industry gaps.” The funds will be used for preclinical trials, with plans to submit an IND application in 2026 and to be listed on the emerging stock market in 2028 as a key member of the “Vaccine Taiwan Team.”

TAIPEI, Aug. 1, 2025 /PRNewswire/ — Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), today announced the completion of a NT$60 million (approx.US$2 million) seed funding round with assistance from Mosaic Venture Lab (MVL). The round, led by Mosaic Seed Fund, also secured a matching investment from the National Development Fund, supported by the SMESA, MOEA, and the NiEA.

Founder and CEO Dr. Min-hsi Lee stated that TaiU’s two main product lines are advancing concurrently. Its lead product, a bivalent enterovirus vaccine, is in joint venture discussions with Vietnam’s largest pharmacy chain, vaccination center chain, and a CDMO. The second, a seasonal influenza Virus-Like Particle (VLP) vaccine, is gaining international attention for its ability to rapidly respond to viral mutations. This potential has attracted a major international pharmaceutical firm for discussions, while domestic MOUs with adjuvant biotech companies are creating powerful synergies to target the hundred-billion-dollar global vaccine market.

Company advisors affirmed its strategy. Dr. Mei-shang Ho, Chairperson of the Taiwan Association for Vaccine Industry (TAVI), noted, “VLP platform technology shortens development timelines. Its high safety and efficacy represent the future of next-generation vaccines and provide a solid foundation for Taiwan to meet the challenges of emerging infectious diseases.”

Professor Peter Chang, a former member of the Control Yuan with experience in vaccine investigations, added, “TaiU successfully links the ‘R&D National Team’ and the ‘Industry National Team,’ demonstrating how Taiwan can build a world-class biomedical industry ecosystem and is a crucial step in proactively expanding Taiwan’s public health and medical strength.”

Johnny Yu, TAVI Vice Chairperson and Managing Director at MVL, concluded, “Taiwan needs more innovative companies like TaiU with flexible, collaborative business models to fill critical industry gaps.” The funds will be used for preclinical trials, with plans to submit an IND application in 2026 and to be listed on the emerging stock market in 2028 as a key member of the “Vaccine Taiwan Team.”

This news is for Australian Media only

• Eflornithine is now reimbursed by the government under Australia’s Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.¹
• Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having high-risk neuroblastoma (HRNB). ³ These children are, on average, just 2 years old, and the average survival rate for those with HRNB is 50%.²

SYDNEY, Aug. 1, 2025 /PRNewswire/ — Norgine, announced today the inclusion of IFINWIL^® (eflornithine) on Australia’s Pharmaceutical Benefits Scheme (PBS). This listing comes just 3 months after receiving registration by the Therapeutic Goods Administration (TGA) and represents a pivotal step in improving access to essential treatments for patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.

Lucy Jones, CEO Neuroblastoma Australia, welcomed the news: “On behalf of all families of children impacted by neuroblastoma, we welcome the PBS listing of IFINWIL^®. We urgently need treatments for children diagnosed with neuroblastoma and this listing ensures every child in Australia has equal access to a new therapy for this aggressive and complex cancer. Providing options to new treatments is critical in ensuring every child diagnosed has the best chance of survival.”

“We thank the Federal Government for their support in ensuring early access to this treatment prior to TGA approval and PBS listing, which enabled children with high-risk disease to access the treatment within a time critical treatment window. We look forward to continued support for children with aggressive cancers.”

HRNB is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life.² Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high-risk neuroblastoma.³ Neuroblastoma originates in the body’s nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands.⁴ It is considered an aggressive tumour because it often spreads to other parts of the body (metastasises). In most cases, it has spread by the time it is diagnosed.⁴

“Eflornithine (DFMO) is a new treatment for high-risk neuroblastoma, an aggressive cancer seen mainly in infants and young children, said Dr. Toby Trahair, Paediatric Oncologist at the Sydney Children’s Hospital. Having access to eflornithine (DFMO) provides clinicians with a much-needed therapeutic option. It’s great to see that this new oral medication will be available to all Australian families through the PBS.”

“The PBS listing of eflornithine is a landmark moment for families affected by high-risk neuroblastoma in Australia,” said Gus Rudolph, General Manager, Australia at Norgine. “This decision reflects the growing recognition of the urgent need for new treatment options in paediatric oncology. High-risk neuroblastoma has limited therapeutic pathways and eflornithine offers a new approach. We are grateful to the Australian Government for providing clinicians with access to this innovative therapy and remain committed to advancing solutions in areas of high unmet medical need.”

Please refer to the IFINWIL^® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.

Parents should speak to their doctor for guidance on the best treatment approach for their child.

Additional Information about IFINWIL^® (eflornithine)

PBS Information. Authority required. Section 100 Highly Specialised Drugs Program. Restrictions Apply. Please refer to the PBS schedule for more details.

Indication: For the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB) who have responded to prior multiagent, multimodality therapy.

Contraindications: Hypersensitivity to eflornithine or to any of the excipients.

Special Warnings and Precautions: myelosuppression, hepatotoxicity, hearing loss / hypoacusis, use in renal impairment, elderly, paediatric patients.

Interactions: No in-vivo drug interaction studies have been performed with other medicinal products.

▼This medicine is subject to additional monitoring due to approval of an extension of indications. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

Dr. Toby Trahair has served on advisory boards and participated in symposia sponsored by Norgine for which compensation was received. In relation to this Norgine media announcement, no compensation was provided to Dr. Trahair, and the opinions expressed are his own. Dr. Trahair has been briefed by Norgine on the approved use of this product.

NOTES TO EDITORS

About IFINWIL^®
IFINWIL^® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients after first line multiagent, multimodality therapy.⁵ IFINWIL^® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development.⁶

For more information on IFINWIL^®, find the Public Summary Document here: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil^®  or speak to your healthcare practitioner.

High-Risk Neuroblastoma (HRNB) Treatment Background
Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.⁷ Although there have been some improvements in survival, the prognosis for children with high risk neuroblastoma is still poor with around 80% of high risk relapses occuring within 2 years from diagnosis, and long-term survival remains low, with only about 15% surviving more than 5 years post-relapse.^7,8,9 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States.¹⁰

About Norgine
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References

^1.  Australian Public Summary Document: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil^® . Accessed July 2025
^2.  https://www.neuroblastoma.org.au/about-key-statistics. Accessed July 2025
^3.  ANZCHOG-Position-Statement-Eflornithine-DFMO-use-for-patients-with-high-risk-neuroblastoma-in-Australia-and-New-Zealand-v2.0-23.08.2024.pdf. Accessed July 2025
^4.  https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Accessed July 2025
^5.  Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. Accessed July 2025
^6.  Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51
^7.  Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
^8.  Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478.
^9.  London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
^10.  FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA. Accessed July 2025

Job Number: AU-ONC-IFW-2500008
Date of preparation: July 2025

This news is for Australian Media only

• Eflornithine is now reimbursed by the government under Australia’s Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.¹
• Approximately 50 children in Australia are diagnosed with neuroblastoma each year, with nearly half classified as having high-risk neuroblastoma (HRNB). ³ These children are, on average, just 2 years old, and the average survival rate for those with HRNB is 50%.²

SYDNEY, Aug. 1, 2025 /PRNewswire/ — Norgine, announced today the inclusion of IFINWIL^® (eflornithine) on Australia’s Pharmaceutical Benefits Scheme (PBS). This listing comes just 3 months after receiving registration by the Therapeutic Goods Administration (TGA) and represents a pivotal step in improving access to essential treatments for patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.

Lucy Jones, CEO Neuroblastoma Australia, welcomed the news: “On behalf of all families of children impacted by neuroblastoma, we welcome the PBS listing of IFINWIL^®. We urgently need treatments for children diagnosed with neuroblastoma and this listing ensures every child in Australia has equal access to a new therapy for this aggressive and complex cancer. Providing options to new treatments is critical in ensuring every child diagnosed has the best chance of survival.”

“We thank the Federal Government for their support in ensuring early access to this treatment prior to TGA approval and PBS listing, which enabled children with high-risk disease to access the treatment within a time critical treatment window. We look forward to continued support for children with aggressive cancers.”

HRNB is a rare but aggressive form of cancer, predominantly affecting children and most commonly presenting in the first 5 years of life.² Each year in Australia, approximately 50 children are diagnosed with neuroblastoma, with about half of these cases being classified as high-risk neuroblastoma.³ Neuroblastoma originates in the body’s nerve cells (neuroblasts) and typically presents as a primary tumour in the adrenal glands.⁴ It is considered an aggressive tumour because it often spreads to other parts of the body (metastasises). In most cases, it has spread by the time it is diagnosed.⁴

“Eflornithine (DFMO) is a new treatment for high-risk neuroblastoma, an aggressive cancer seen mainly in infants and young children, said Dr. Toby Trahair, Paediatric Oncologist at the Sydney Children’s Hospital. Having access to eflornithine (DFMO) provides clinicians with a much-needed therapeutic option. It’s great to see that this new oral medication will be available to all Australian families through the PBS.”

“The PBS listing of eflornithine is a landmark moment for families affected by high-risk neuroblastoma in Australia,” said Gus Rudolph, General Manager, Australia at Norgine. “This decision reflects the growing recognition of the urgent need for new treatment options in paediatric oncology. High-risk neuroblastoma has limited therapeutic pathways and eflornithine offers a new approach. We are grateful to the Australian Government for providing clinicians with access to this innovative therapy and remain committed to advancing solutions in areas of high unmet medical need.”

Please refer to the IFINWIL^® Consumer Medicines Information (CMI) for full safety information on risks, side effects and precautions including the risk of low red blood cells (anaemia), low neutrophils (blood cells that fight infection), low platelets (clotting cells), increase in liver enzymes, and hearing loss or problems balancing.

Parents should speak to their doctor for guidance on the best treatment approach for their child.

Additional Information about IFINWIL^® (eflornithine)

PBS Information. Authority required. Section 100 Highly Specialised Drugs Program. Restrictions Apply. Please refer to the PBS schedule for more details.

Indication: For the treatment of adults and paediatric patients with high-risk neuroblastoma (HRNB) who have responded to prior multiagent, multimodality therapy.

Contraindications: Hypersensitivity to eflornithine or to any of the excipients.

Special Warnings and Precautions: myelosuppression, hepatotoxicity, hearing loss / hypoacusis, use in renal impairment, elderly, paediatric patients.

Interactions: No in-vivo drug interaction studies have been performed with other medicinal products.

▼This medicine is subject to additional monitoring due to approval of an extension of indications. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.

Dr. Toby Trahair has served on advisory boards and participated in symposia sponsored by Norgine for which compensation was received. In relation to this Norgine media announcement, no compensation was provided to Dr. Trahair, and the opinions expressed are his own. Dr. Trahair has been briefed by Norgine on the approved use of this product.

NOTES TO EDITORS

About IFINWIL^®
IFINWIL^® has been investigated for use as a post maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients after first line multiagent, multimodality therapy.⁵ IFINWIL^® is a therapy that blocks an enzyme called ornithine decarboxylase (ODC) responsible for producing polyamines, which are important to tumour growth and development.⁶

For more information on IFINWIL^®, find the Public Summary Document here: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil^®  or speak to your healthcare practitioner.

High-Risk Neuroblastoma (HRNB) Treatment Background
Children diagnosed with HRNB undergo an intense treatment regimen that still leaves them vulnerable to relapse and death.⁷ Although there have been some improvements in survival, the prognosis for children with high risk neuroblastoma is still poor with around 80% of high risk relapses occuring within 2 years from diagnosis, and long-term survival remains low, with only about 15% surviving more than 5 years post-relapse.^7,8,9 Avoiding relapse is key to long-term survival, and until now, there have been no approved therapies for the post maintenance treatment period in major markets outside of the United States.¹⁰

About Norgine
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people’s lives drives everything we do, and our European experience, fully integrated infrastructure and exceptional partnership approach enable us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped more than 25 million patients around the world in 2022 and generated €530 million in net product sales, a growth of nearly 5% over 2021.

Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.

NORGINE and the sail logo are trademarks of the Norgine group of companies.

References

^1.  Australian Public Summary Document: Pharmaceutical Benefits Scheme (PBS) | Eflornithine; Tablet 192 mg (as hydrochloride); Ifinwil^® . Accessed July 2025
^2.  https://www.neuroblastoma.org.au/about-key-statistics. Accessed July 2025
^3.  ANZCHOG-Position-Statement-Eflornithine-DFMO-use-for-patients-with-high-risk-neuroblastoma-in-Australia-and-New-Zealand-v2.0-23.08.2024.pdf. Accessed July 2025
^4.  https://rarediseases.info.nih.gov/diseases/7185/neuroblastoma. Accessed July 2025
^5.  Clinical Trial NCT02395666; Preventative trial of difluoromethylornithine (DFMO) in high risk patients with neuroblastoma that is in remission. Available from: Study Details | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | ClinicalTrials.gov. Accessed July 2025
^6.  Meyskens FL Jr, Gerner EW. Development of Difluoromethylornithine (DFMO) as a Chemoprevention Agent. Clin Cancer Res. 1999 May;5(5):945-51
^7.  Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048-57.
^8.  Desai A, et al. Outcomes Following GD2-Directed Post consolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children’s Oncology Group. J Clin Oncol. 2022 Jul; JCO2102478.
^9.  London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer. 2017;123:4914-23.
^10.  FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma | FDA. Accessed July 2025

Job Number: AU-ONC-IFW-2500008
Date of preparation: July 2025